Fixed price, unfixed volume: the company is locked into a rate while the amount it can sell against it is climbing
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes a situation where the price/rate/fee is already fixed or contractually set, and the quantity of business at that rate is currently rising or about to rise, so that results scale with volume. The transcript mentions several revenue streams: ICP (liquid biopsy), Pathology Services, IV-Cell, HemeScreen. For each, we need to see if there is a fixed rate and increasing volume. - ICP: They have a co-marketing agreement with Perkin Elmer. They estimate 2019 revenues between several hundreds to several million dollars from market penetration. But is the rate fixed? They talk about market penetration, but no specific contract terms. The agreement is co-marketing, not necessarily a fixed fee per unit. They mention "revenue potential" but not a settled rate. Also, volume is expected to grow but not yet secured. So not clear. - Pathology Services: They have a sales force, revenue growing 50% from previous quarter. They expect to exceed $1 million per quarter by mid-2019. But is the rate fixed? Pathology services typically have fee schedules, but the transcript doesn't explicitly state that the price per test is contractually set. They talk about growing customer base and conversion rates. The volume is increasing, but the rate is not explicitly described as fixed. They might have standard pricing, but not mentioned. - IV-Cell: They are commercializing, but no mention of fixed pricing or volume ramp. - HemeScreen: They launched in their lab, received orders. They expect revenues in excess of $1 million in 2019. Again, no explicit mention of fixed rate per test. They say "market volume and revenue numbers of the current inferior test" but not that their price is set. The question asks: "does management describe a situation in which THE PRICE, RATE, OR FEE THE COMPANY EARNS ON A MEANINGFUL PART OF ITS BUSINESS IS ALREADY FIXED OR CONTRACTUALLY SET, while THE QUANTITY OF BUSINESS THE COMPANY CAN EARN THAT RATE ON IS CURRENTLY RISING OR ABOUT TO RISE" We need to find a specific instance where management explicitly states that the rate is fixed and volume is increasing. The transcript does not explicitly state that any of these have a fixed price per unit.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
ABR · Q4 2016 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing the Agency Business servicing portfolio at $13.6 billion with a fixed 48 basis point weighted average servicing fee that is already contracted and recurring. They explicitly note the portfolio is growing through recent originations, including $700 million closed in December, which will drive higher servicing income in Q 1. Management states they expect the portfolio to generate over $65 million annually and references growth from 2015 levels, indicating the reported Q4 results reflect a lower average volume during the quarter while the settled economics now scale with the increasing volume arriving in Q1.
FIX · Q1 2017 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing a situation where pricing is stable and contracts (backlog) lock in rates, while volume is rising through backlog growth and upcoming organic work. The Q1 results reflect lower seasonal volume, with the backlog supporting higher throughput ahead. This fits the criteria of settled rates on meaningful contracted business with 13% backlog increase driving volume step-up.
CHE · Q3 2022 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES Management describes Medicare reimbursement rates as already fixed by regulation (CMS), with the volume side now rising through a first significant expansion of clinical staff and patient capacity since the pandemic, plus strengthening admissions and weekly ADC growth in the second half. The reported quarter reflects lower volume (ADC down 4.